MedTrace Logo

Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

NCT00265889 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2013-11-20

Study results available
· View outcomes & findings →

Summary

RATIONALE: Giving two autologous stem cell transplants (one after the other) may be an effective treatment for Hodgkin's lymphoma.

PURPOSE: This phase II trial is studying how well giving two autologous stem cell transplants works in treating patients with progressive or recurrent Hodgkin's lymphoma.

Conditions

Interventions

BIOLOGICAL

filgrastim

480 mcg beginning day +5

DRUG

busulfan

11.2 mg/kg; 0.8 mg/kg IV q6h X 14 doses

DRUG

cyclophosphamide

60 mg/kg IV over 2 hours x 2 days

DRUG

etoposide

60 mg/kg, IV

DRUG

melphalan

150mg/m2 in NS at a concentration of 0.4mg/cc infused over 60 minutes.

PROCEDURE

autologous-autologous tandem hematopoietic stem cell transplantation

autologous-autologous tandem hematopoietic stem cell transplantation

RADIATION

radiation therapy

radiation therapy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Case Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Brian J. Bolwell, MD · Cleveland Clinic Taussig Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-02-28
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00265889 on ClinicalTrials.gov